The FASEB Journal News - May 2018

June 01, 2018

In the News

Celecoxib shows potential benefit for Duchenne muscular dystrophy


New research in The FASEB Journal found that the FDA-approved anti-inflammatory drug Celecoxib (also known as Celebrex) had beneficial effects on the muscle function of mdx mice, a mouse model affected by muscular dystrophy. Celecoxib treatment of the mice also increased a protein called utrophin, which has been shown to improve dystrophic muscle and effectively compensate for the lack of dystrophin, a large protein that plays an important role in general muscle maintenance.

Press release | Abstract


Meet the Editor

Paul A. Insel, MD

Editorial Board

UC San Diego

Paul A. Insel received his medical degree from the University of Michigan, subsequent clinical training on the Harvard Medical Service at Boston City Hospital and research training at NIH and the Cardiovascular Research Institute and Departments of Medicine and Pharmacology at UC San Francisco.

He is currently Distinguished Professor of Pharmacology and Medicine and Co-Director of the Medical Scientist (MD/PhD) Training Program at UC San Diego. Dr. Insel holds a Doc. Hon. Causa from the University of Paris, is a Fellow, American Association for the Advancement of Science and has received major awards from the American Society for Pharmacology and Experimental Therapeutics and the American Physiological Society. His major research efforts have focused on studies of G-protein-coupled receptors (GPCRs) with respect to their expression, signaling mechanisms, regulation, effects in target cells and roles in health and disease. These efforts have been directed at GPCRs, heterotrimeric G-proteins, G-protein-regulated effectors, the compartmentation of signaling molecules in lipid raft/caveolin domains, cAMP actions on cells, and the use of “omics” approaches to define GPCR expression and the cAMP-regulated transcriptome and proteome. Expertise terms: GPCR, heterotrimeric G proteins, cyclic AMP, caveolae 


Trending Articles

Dose translation from animal to human studies revisited


Oxidative DNA damage: mechanisms, mutation, and disease


Cellular mechanotransduction: putting all the pieces together again



The Business of The FASEB Journal

FASEB BioAdvances Now Accepting Submissions

Founding Editor-in-Chief Jasna Markovac, PhD, invites you to submit to FASEB's newly launched open access journal, FASEB BioAdvances. To learn more and review author guidelines, visit the website.


The opinions expressed in editorials, essays, letters to the editor, and other articles described in this communication do not necessarily reflect the opinions of FASEB or its member societies.

Follow us!


Categories: The FASEB Journal News;